ペン型注入器市場 – 2030年までの世界予測

Report Overview

The global injection pen market is projected to reach USD 74.1 billion by 2030 from USD 47.0 billion in 2024, at a CAGR of 7.9% during the forecast period.

世界のペン型注入器市場は、予測期間中のCAGR 7.9%で、2024年の470億米ドルから2030年までに741億米ドルに達すると予測されています。

The rapid growth in the geriatric population globally and the significant rise in the patients with chronic diseases such as diabetes and growth hormone disorders are expected to boost the demand for injection pen market. Moreover, gradual rise in utilization of self administration and increased focus on patient centric dsign and patient compliance are likely to support the market growth. Advancements in injection pen technology, new product launches, favourable reimbursement and government policies, investments in healthcare infrastructure, and initiatives to enhance the accessibility and affordability  of injection pen is anticipated to fuel the market growth.

“The reusable injection pen segment of injection pen market  to grow with the highest CAGR during the forecast period.”

Based on the injection pen market, the reusable injection pen segment is anticipated to grow at significant rate during forecast period. Due to increasing prevalence of chronic disease, ease of use and durability of reusable injection pen. These pens are more economical than disposable pens as they can be used multiple times by replacing the drug cartridge.Also, due to increased preference in self-administration and home care, there has been significant development and advancement in reusable injection pens. These factors are fostering the growth of injectable drug delivery at higher pace.

“The GLP-1 segment of diabetes therapy type segment to capture the largest market share of injection pen market.”

Based on therapy the injection pen market is segmented into into diabetes, growth hormone therapy, fertility, osteoporosis, obesity, and other therapies. The diabetes segment is  further segmented into insulin and GLP-1 therapy types. GLP-1 segment register the higher CAGR during the forecast period. GLP-1-based therapies are used in treating diabetes mellitus due to their physiological properties and  delivered through pen devices using thin and short needles. Owing to high R&D investments for developing GLP-1 therapies by prominent market players and recent advancements in GLP-1 injection pens are likely to propel the growth of this segment.

“North America accounted for the largest share of the injection pen market by region.”

The global injection penmarket is segmented into five  major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for injection pen, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The largest share of North America is  attributed to the  high disease burden of chronic disease such as diabetes contributing  to a larger pool of patients requiring injection pen products. The presence of numerous potential market giants and favorable reimbursement policy in the region is likely to promote the growth of injection pen market in North America.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1–25%, Tier 2–30%, and Tier 3– 45%
• By Designation: C-level–26%, Director-level–30%, and Others–44%
• By Region: North America–40%, Europe–31%, Asia Pacific–20%, Latin America–6%, and the Middle East & Africa–3%

The major players operating in the injection pen market market are Novo Nordisk A/S (Denmark), Eli Lilly and Company (US), Sanofi (France), Ypsomed Holding AG (Switzerland), Becton, Dickinson and Company (US), Merck KGaA (Germany), AstraZeneca (UK), Owen Mumford (UK), Heselmeier (Germany), Sun Pharmaceutical Industries Ltd. (India), Pfizer Inc. (US), Biocon (India), Lupin (India), Wockhardt Ltd. (India) and Medtronic (Ireland).

Research Coverage

This report studies the injection pen market based on type, therapy, end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:

Analysis of Key divers (increasing prevalence of chronic disease, technological advancement in injection pens, new product launches, favourable reimbursement scenario and government initiatives),  restraints (stringent regulatory requirement , Opportunities (emerging markets, increasing focus on patient centric design and connected device ) , Challenge (lack of training and awareness, risk of injection site reactions)

• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the injection pen market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the injection pen market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the injection pen market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

Table of Contents

1            INTRODUCTION            22

1.1         STUDY OBJECTIVES      22

1.2         MARKET DEFINITION   22

1.2.1      INCLUSIONS AND EXCLUSIONS 22

1.3         MARKET SCOPE             23

1.3.1      MARKETS COVERED     23

1.3.2      YEARS CONSIDERED     24

1.3.3      CURRENCY CONSIDERED          24

1.4         STAKEHOLDERS            25

1.5         SUMMARY OF CHANGES            25

2            RESEARCH METHODOLOGY     26

2.1         RESEARCH DATA           26

2.1.1      SECONDARY DATA       27

2.1.1.1   Key data from secondary sources     28

2.1.2      PRIMARY DATA 28

2.1.2.1   Key industry insights          29

2.1.2.2   Breakdown of primary interviews     30

2.2         MARKET SIZE ESTIMATION       31

2.2.1      FINISHED FORMULATIONS       31

2.2.2      INJECTION PEN DEVICES           34

2.2.2.1   Top-down approach          36

2.3         GROWTH RATE PROJECTIONS  36

2.4         DATA TRIANGULATION             38

2.5         RESEARCH ASSUMPTIONS         39

2.6         RESEARCH LIMITATIONS           39

2.6.1      PARAMETRIC LIMITATIONS      39

2.6.2      SCOPE-RELATED LIMITATIONS             39

2.7         RISK ASSESSMENT         40

3            EXECUTIVE SUMMARY 41

4            PREMIUM INSIGHTS      45

4.1         INJECTION PEN MARKET OVERVIEW    45

4.2         ASIA PACIFIC: INJECTION PEN MARKET, BY THERAPY AND COUNTRY, 2023      46

4.3         INJECTION PEN MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES              47

4.4         INJECTION PEN MARKET: DEVELOPED VS. DEVELOPING MARKETS              47

5            MARKET OVERVIEW     48

5.1         MARKET DYNAMICS     48

5.1.1      DRIVERS            49

5.1.1.1   Surge in chronic diseases   49

5.1.1.2   Favorable reimbursement and government support      50

5.1.1.3   Emergence of new technologies       51

5.1.2      RESTRAINTS     51

5.1.2.1   Stringent regulatory requirements   51

5.1.3      OPPORTUNITIES           52

5.1.3.1   Rising focus on patient-centric design and connected devices    52

5.1.3.2   Growth opportunities in emerging economies 52

5.1.4      CHALLENGES   53

5.1.4.1   Lack of training and education         53

5.1.4.2   Need to minimize side effects and injection-site reactions          54

5.2         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 55

5.3         TECHNOLOGY ANALYSIS           56

5.3.1      KEY TECHNOLOGIES    56

5.3.1.1   Connectivity and smart features       56

5.3.1.2   Pen injector materials        56

5.3.2      COMPLEMENTARY TECHNOLOGIES     57

5.3.2.1   In-built functions 57

5.3.2.2   Wireless connectivity         57

5.3.2.3   Smart caps and attachments             57

5.3.3      ADJACENT TECHNOLOGIES      58

5.3.3.1   Autoinjectors       58

5.3.3.2   Insulin pumps      58

5.3.3.3   Wearable insulin injectors  58

5.4         SUPPLY CHAIN ANALYSIS          59

5.5         TRADE ANALYSIS          60

5.5.1      IMPORT DATA 60

5.5.2      EXPORT DATA 61

5.6         PORTER’S FIVE FORCES ANALYSIS         61

5.6.1      INTENSITY OF COMPETITIVE RIVALRY 62

5.6.2      BARGAINING POWER OF SUPPLIERS     62

5.6.3      BARGAINING POWER OF BUYERS           63

5.6.4      THREAT OF SUBSTITUTES         63

5.6.5      THREAT OF NEW ENTRANTS    63

5.7         VALUE CHAIN ANALYSIS            64

5.8         REGULATORY LANDSCAPE       66

5.8.1      NORTH AMERICA          66

5.8.1.1   US         66

5.8.1.2   Canada  67

5.8.2      EUROPE             68

5.8.3      ASIA PACIFIC    68

5.8.3.1   Japan     68

5.8.3.2   China     69

5.8.3.3   India      70

5.8.4      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          71

5.9         PATENT ANALYSIS        74

5.9.1      PATENT PUBLICATION TRENDS FOR INJECTION PENS 74

5.9.2      JURISDICTION AND TOP APPLICANT ANALYSIS             75

5.10       PRICING ANALYSIS        76

5.10.1    AVERAGE SELLING PRICE OF INSULIN PENS, BY KEY PLAYER    76

5.10.2    AVERAGE SELLING PRICE OF GLP-1 PENS, BY KEY PLAYER         77

5.10.3    AVERAGE SELLING PRICE, BY THERAPY             77

5.10.4    AVERAGE SELLING PRICE, BY REGION  78

5.11       KEY CONFERENCES AND EVENTS, 2024–2025     78

5.12       KEY STAKEHOLDERS AND BUYING CRITERIA    79

5.12.1    KEY STAKEHOLDERS IN BUYING PROCESS         79

5.12.2    BUYING CRITERIA         80

5.13       ECOSYSTEM ANALYSIS 80

5.14       CASE STUDY ANALYSIS 81

5.15       REIMBURSEMENT ANALYSIS     82

5.16       UNMET NEEDS IN INJECTION PEN MARKET      83

5.17       END-USER EXPECTATIONS IN INJECTION PEN MARKET             84

5.18       IMPACT OF AI ON INJECTION PEN MARKET      84

5.19       INVESTMENT AND FUNDING SCENARIO            85

6            INJECTION PEN MARKET, BY TYPE        86

6.1         INTRODUCTION            87

6.2         DISPOSABLE INJECTION PENS  88

6.2.1      GROWING GERIATRIC POPULATION TO DRIVE MARKET           88

6.3         REUSABLE INJECTION PENS      91

6.3.1      ONGOING TECHNOLOGICAL ADVANCEMENTS TO FUEL MARKET              91

7            INJECTION PEN MARKET, BY THERAPY 94

7.1         INTRODUCTION            95

7.2         DIABETES         95

7.2.1      INSULIN             98

7.2.1.1   Rising prevalence of diabetes to aid market growth      98

7.2.2      GLUCAGON-LIKE PEPTIDE-1    100

7.2.2.1   Rising focus on research & development to propel market          100

7.3         GROWTH HORMONE THERAPY 102

7.3.1      INCREASED SUPPORT FOR CO-PAYMENT OF DRUG DELIVERY SERVICES TO FUEL MARKET     102

7.4         OSTEOPOROSIS             104

7.4.1      GROWING UPTAKE FOR TREATING BONE ISSUES TO SUPPORT MARKET            104

7.5         FERTILITY         106

7.5.1      CHANGING LIFESTYLE AND RISING INCIDENCE OF IMPOTENCE TO BOOST DEMAND           106

7.6         OBESITY            108

7.6.1      RISING PREVALENCE OF OBESITY IN HIGH-INCOME COUNTRIES TO DRIVE MARKET 108

7.7         OTHER THERAPIES       110

8            INJECTION PEN MARKET, BY END USER              112

8.1         INTRODUCTION            113

8.2         HOME CARE SETTINGS 113

8.2.1      TREND OF SELF-ADMINISTRATION TO STIMULATE GROWTH  113

8.3         HOSPITALS & CLINICS  115

8.3.1      NEEDLESTICK INJURIES AND UNSAFE INJECTION PRACTICES TO PROPEL DEMAND         115

9            INJECTION PEN MARKET, BY REGION   117

9.1         INTRODUCTION            118

9.2         NORTH AMERICA          119

9.2.1      US         121

9.2.1.1   Increasing prevalence of diabetes and infertility to drive market 121

9.2.2      CANADA            123

9.2.2.1   Booming healthcare expenditure to fuel market           123

9.3         EUROPE             125

9.3.1      GERMANY         127

9.3.1.1   Advanced healthcare system and insurance coverage to boost market       127

9.3.2      FRANCE             129

9.3.2.1   Growing incidence of chronic diseases to foster growth              129

9.3.3      UK         131

9.3.3.1   Rising focus on educating patients and staff about safe use of injection pens to aid growth   131

9.3.4      ITALY   133

9.3.4.1   Heterogenous reimbursement policies to hinder market growth 133

9.3.5      SPAIN   135

9.3.5.1   Favorable healthcare regulations to aid growth             135

9.3.6      REST OF EUROPE           137

9.4         ASIA PACIFIC    138

9.4.1      JAPAN  141

9.4.1.1   Universal healthcare coverage to fuel market 141

9.4.2      CHINA  143

9.4.2.1   Growing focus on public health services to support market growth           143

9.4.3      INDIA   145

9.4.3.1   Rapid population growth to drive market       145

9.4.4      SOUTH KOREA 147

9.4.4.1   Surge in collaborations among companies to increase adoption of injectables              147

9.4.5      AUSTRALIA       149

9.4.5.1   Increasing regulatory approvals to augment growth      149

9.4.6      REST OF ASIA PACIFIC  151

9.5         LATIN AMERICA             152

9.5.1      BRAZIL 154

9.5.1.1   Surge in obesity issues to stimulate market growth       154

9.5.2      MEXICO             156

9.5.2.1   Increasing incidence of chronic diseases to drive growth            156

9.5.3      REST OF LATIN AMERICA          158

9.6         MIDDLE EAST & AFRICA             159

9.6.1      GCC COUNTRIES           162

9.6.1.1   Growing preference among patients for self-administration to drive market              162

9.6.2      REST OF MIDDLE EAST & AFRICA           164

10          COMPETITIVE LANDSCAPE       166

10.1       OVERVIEW        166

10.2       KEY PLAYER STRATEGY/RIGHT TO WIN             166

10.2.1    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN INJECTION PEN MARKET    167

10.3       REVENUE ANALYSIS      168

10.4       MARKET SHARE ANALYSIS         168

10.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   170

10.5.1    STARS  171

10.5.2    EMERGING LEADERS    171

10.5.3    PERVASIVE PLAYERS     171

10.5.4    PARTICIPANTS 171

10.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      173

10.5.5.1 Company footprint            173

10.5.5.2 Type footprint     174

10.5.5.3 Therapy footprint 175

10.5.5.4 Region footprint  176

10.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          177

10.6.1    PROGRESSIVE COMPANIES       177

10.6.2    RESPONSIVE COMPANIES          177

10.6.3    DYNAMIC COMPANIES 177

10.6.4    STARTING BLOCKS       178

10.6.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023             179

10.7       COMPANY VALUATION AND FINANCIAL METRICS        180

10.7.1    FINANCIAL METRICS    180

10.7.2    COMPANY VALUATION 180

10.8       BRAND/PRODUCT COMPARISON          181

10.9       COMPETITIVE SCENARIO          182

10.9.1    PRODUCT LAUNCHES AND APPROVALS            182

10.9.2    DEALS  182

10.9.3    EXPANSIONS    183

10.9.4    OTHER DEVELOPMENTS           184

11          COMPANY PROFILES    185

11.1       KEY PLAYERS   185

11.1.1    NOVO NORDISK A/S      185

11.1.1.1 Business overview 185

11.1.1.2 Products offered  186

11.1.1.3 Recent developments         187

11.1.1.3.1            Product launches and approvals       187

11.1.1.3.2            Deals     187

11.1.1.4 MnM view           187

11.1.1.4.1            Key strengths       187

11.1.1.4.2            Strategic choices  187

11.1.1.4.3            Weaknesses and competitive threats 188

11.1.2    ELI LILLY AND COMPANY          189

11.1.2.1 Business overview 189

11.1.2.2 Products offered  190

11.1.2.3 Recent developments         191

11.1.2.3.1            Deals     191

11.1.2.3.2            Expansions          191

11.1.2.4 MnM view           192

11.1.2.4.1            Key strengths       192

11.1.2.4.2            Strategic choices  192

11.1.2.4.3            Weaknesses and competitive threats 192

11.1.3    SANOFI 193

11.1.3.1 Business overview 193

11.1.3.2 Products offered  194

11.1.3.3 Recent developments         195

11.1.3.3.1            Deals     195

11.1.3.4 MnM view           195

11.1.3.4.1            Key strengths       195

11.1.3.4.2            Strategic choices  195

11.1.3.4.3            Weaknesses and competitive threats 195

11.1.4    YPSOMED HOLDING AG            196

11.1.4.1 Business overview 196

11.1.4.2 Products offered  197

11.1.4.3 Recent developments         198

11.1.4.3.1            Expansions          198

11.1.4.3.2            Other developments          198

11.1.4.4 MnM view           198

11.1.4.4.1            Key strengths       198

11.1.4.4.2            Strategic choices  199

11.1.4.4.3            Weaknesses and competitive threats 199

11.1.5    BECTON, DICKINSON AND COMPANY  200

11.1.5.1 Business overview 200

11.1.5.2 Products offered  201

11.1.5.3 MnM view           202

11.1.5.3.1            Key strengths       202

11.1.5.3.2            Strategic choices  202

11.1.5.3.3            Weaknesses and competitive threats 202

11.1.6    MERCK KGAA   203

11.1.6.1 Business overview 203

11.1.6.2 Products offered  204

11.1.7    ASTRAZENECA 205

11.1.7.1 Business overview 205

11.1.7.2 Products offered  206

11.1.7.3 Recent developments         207

11.1.7.3.1            Product launches and approvals       207

11.1.8    OWEN MUMFORD         208

11.1.8.1 Business overview 208

11.1.8.2 Products offered  208

11.1.9    HASELMEIER    209

11.1.9.1 Business overview 209

11.1.9.2 Products offered  209

11.1.10  SUN PHARMACEUTICAL INDUSTRIES LTD.        210

11.1.10.1             Business overview 210

11.1.10.2             Products offered  211

11.1.11  PFIZER INC.       212

11.1.11.1             Business overview 212

11.1.11.2             Products offered  213

11.1.12  BIOCON             214

11.1.12.1             Business overview 214

11.1.12.2             Products offered  215

11.1.12.3             Recent developments         216

11.1.12.3.1          Product launches and approvals       216

11.1.12.3.2          Deals     216

11.1.13  LUPIN  217

11.1.13.1             Business overview 217

11.1.13.2             Products offered  218

11.1.14  WOCKHARDT LTD.       219

11.1.14.1             Business overview 219

11.1.14.2             Products offered  220

11.1.15  MEDTRONIC     221

11.1.15.1             Business overview 221

11.1.15.2             Products offered  222

11.1.15.3             Recent developments         223

11.1.15.3.1          Product launches and approvals       223

11.2       OTHER PLAYERS           224

11.2.1    GERRESHEIMER AG       224

11.2.2    SHAILY ENGINEERING PLASTICS LTD.  225

11.2.3    SHL MEDICAL AG          226

11.2.4    EMPERRA GMBH E-HEALTH TECHNOLOGIES   227

11.2.5    NEMERA FRANCE SAS   228

11.2.6    JIANGSU DELFU MEDICAL DEVICE CO., LTD.    229

11.2.7    SOLTEAM MEDICAL      230

11.2.8    PHILLIPS-MEDISIZE – A MOLEX COMPANY         231

11.2.9    STEVANATO GROUP     232

11.2.10  WANHAI MEDICAL INSTRUMENTS CO., LTD.     233

12          APPENDIX         234

12.1       DISCUSSION GUIDE      234

12.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             238

12.3       CUSTOMIZATION OPTIONS      240

12.4       RELATED REPORTS       241

12.5       AUTHOR DETAILS         242

LIST OF TABLES

TABLE 1             INJECTION PEN MARKET: INCLUSIONS AND EXCLUSIONS              22

TABLE 2             USD CONVERSION RATES, 2021–2023     24

TABLE 3             CLASSIFICATION OF PEN INJECTORS    56

TABLE 4             IMPORT DATA FOR MEDICAMENTS CONTAINING INSULIN IN MEASURED DOSES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)     60

TABLE 5             EXPORT DATA FOR MEDICAMENTS CONTAINING INSULIN IN MEASURED DOSES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND)     61

TABLE 6             INJECTION PEN MARKET: PORTER’S FIVE FORCES ANALYSIS              61

TABLE 7             US FOOD AND DRUG ADMINISTRATION: MEDICAL DEVICE CLASSIFICATION           66

TABLE 8             US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS              66

TABLE 9             CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS           67

TABLE 10           JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICALS AND MEDICAL DEVICES AGENCY 69

TABLE 11           CHINA: REGULATORY BODIES FOR MEDICAL DEVICE APPROVAL        69

TABLE 12           CHINA: CLASSIFICATION OF MEDICAL DEVICES             70

TABLE 13           NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 71

TABLE 14           EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 71

TABLE 15           ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 72

TABLE 16           LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 73

TABLE 17           MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,

AND OTHER ORGANIZATIONS 73

TABLE 18           AVERAGE SELLING PRICE TREND OF INJECTION PENS, BY THERAPY, 2023 (USD)   77

TABLE 19           AVERAGE SELLING PRICE TREND OF INJECTION PENS, BY REGION,

2021–2023 (USD)             78

TABLE 20           KEY CONFERENCES AND EVENTS, 2024–2025     78

TABLE 21           INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER    79

TABLE 22           KEY BUYING CRITERIA, BY END USER    80

TABLE 23           CASE STUDY 1: USE OF UNOPEN INJECTOR PEN FOR ACCURATE

DOSAGE OF INSULIN    81

TABLE 24           CASE STUDY 2: ADOPTION OF PEN INJECTOR PLATFORMS FOR

IMPROVED THERAPEUTIC OUTCOMES 82

TABLE 25           REIMBURSEMENT CODES          82

TABLE 26           END-USER EXPECTATIONS       84

TABLE 27           INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)              87

TABLE 28           INJECTION PEN DEVICES MARKET, BY TYPE, 2022–2030 (USD MILLION)          87

TABLE 29           DISPOSABLE INJECTION PENS AVAILABLE IN MARKET 88

TABLE 30           INJECTION PEN MARKET FOR DISPOSABLE INJECTION PENS, BY COUNTRY,

2022–2030 (USD MILLION)          89

TABLE 31           INJECTION PEN MARKET FOR DISPOSABLE INJECTION PEN DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)        90

TABLE 32           REUSABLE INJECTION PENS AVAILABLE IN MARKET     91

TABLE 33           INJECTION PEN MARKET FOR REUSABLE INJECTION PENS, BY COUNTRY,

2022–2030 (USD MILLION)          92

TABLE 34           INJECTION PEN MARKET FOR REUSABLE INJECTION PEN DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)        93

TABLE 35           INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          95

TABLE 36           INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          96

TABLE 37           INJECTION PEN MARKET FOR DIABETES THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)          97

TABLE 38           INJECTION PENS FOR INSULIN AVAILABLE IN MARKET 98

TABLE 39           INJECTION PEN MARKET FOR INSULIN THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)          99

TABLE 40           INJECTABLE DRUGS FOR GLUCAGON-LIKE PEPTIDE-1 THERAPY IN

CLINICAL TRIAL PHASES           100

TABLE 41           INJECTION PEN MARKET FOR GLUCAGON-LIKE PEPTIDE-1 THERAPY, BY COUNTRY, 2022–2030 (USD MILLION)       101

TABLE 42           INJECTION PENS FOR GROWTH HORMONE THERAPY AVAILABLE IN MARKET 102

TABLE 43           INJECTION PEN MARKET FOR GROWTH HORMONE THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)        103

TABLE 44           INJECTION PEN MARKET FOR OSTEOPOROSIS THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)          105

TABLE 45           INJECTION PEN MARKET FOR FERTILITY THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)          107

TABLE 46           INJECTION PEN MARKET FOR OBESITY THERAPY, BY COUNTRY,

2022–2030 (USD MILLION)          109

TABLE 47           INJECTION PEN MARKET FOR OTHER THERAPIES, BY COUNTRY,

2022–2030 (USD MILLION)          111

TABLE 48           INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          113

TABLE 49           INJECTION PEN MARKET FOR HOME CARE SETTINGS, BY COUNTRY,

2022–2030 (USD MILLION)          114

TABLE 50           INJECTION PEN MARKET FOR HOSPITALS & CLINICS, BY COUNTRY,

2022–2030 (USD MILLION)          116

TABLE 51           INJECTION PEN MARKET, BY REGION, 2022–2030 (USD MILLION)          118

TABLE 52           NORTH AMERICA: INJECTION PEN MARKET, BY COUNTRY,

2022–2030 (USD MILLION)          120

TABLE 53           NORTH AMERICA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)     120

TABLE 54           NORTH AMERICA: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          120

TABLE 55           NORTH AMERICA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2022–2030 (USD MILLION)  121

TABLE 56           NORTH AMERICA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          121

TABLE 57           US: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          122

TABLE 58           US: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          122

TABLE 59           US: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          123

TABLE 60           US: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          123

TABLE 61           CANADA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          124

TABLE 62           CANADA: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 124

TABLE 63           CANADA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          125

TABLE 64           CANADA: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 125

TABLE 65           EUROPE: INJECTION PEN MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 126

TABLE 66           EUROPE: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          126

TABLE 67           EUROPE: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 126

TABLE 68           EUROPE: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          127

TABLE 69           EUROPE: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 127

TABLE 70           GERMANY: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          128

TABLE 71           GERMANY: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 128

TABLE 72           GERMANY: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          129

TABLE 73           GERMANY: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 129

TABLE 74           FRANCE: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          130

TABLE 75           FRANCE: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 130

TABLE 76           FRANCE: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          130

TABLE 77           FRANCE: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 131

TABLE 78           UK: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          132

TABLE 79           UK: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          132

TABLE 80           UK: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          132

TABLE 81           UK: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          133

TABLE 82           ITALY: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          133

TABLE 83           ITALY: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          134

TABLE 84           ITALY: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          134

TABLE 85           ITALY: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          134

TABLE 86           SPAIN: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          135

TABLE 87           SPAIN: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          136

TABLE 88           SPAIN: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          136

TABLE 89           SPAIN: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          136

TABLE 90           REST OF EUROPE: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)     137

TABLE 91           REST OF EUROPE: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          137

TABLE 92           REST OF EUROPE: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2022–2030 (USD MILLION)  138

TABLE 93           REST OF EUROPE: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          138

TABLE 94           ASIA PACIFIC: INJECTION PEN MARKET, BY COUNTRY, 2022–2030 (USD MILLION)     140

TABLE 95           ASIA PACIFIC: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION) 140

TABLE 96           ASIA PACIFIC: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)     140

TABLE 97           ASIA PACIFIC: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          141

TABLE 98           ASIA PACIFIC: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)     141

TABLE 99           JAPAN: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          142

TABLE 100         JAPAN: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          142

TABLE 101         JAPAN: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          143

TABLE 102         JAPAN: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 143

TABLE 103         CHINA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          144

TABLE 104         CHINA: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          144

TABLE 105         CHINA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          145

TABLE 106         CHINA: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 145

TABLE 107         INDIA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          146

TABLE 108         INDIA: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)          146

TABLE 109         INDIA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          147

TABLE 110         INDIA: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION)          147

TABLE 111         SOUTH KOREA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION) 148

TABLE 112         SOUTH KOREA: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION)     148

TABLE 113         SOUTH KOREA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          148

TABLE 114         SOUTH KOREA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          149

TABLE 115         AUSTRALIA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION) 149

TABLE 116         AUSTRALIA: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 150

TABLE 117         AUSTRALIA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030(USD MILLION)           150

TABLE 118         AUSTRALIA: INJECTION PEN MARKET, BY END USER, 2022–2030(USD MILLION)      150

TABLE 119         REST OF ASIA PACIFIC: INJECTION PEN MARKET, BY TYPE,

2022–2030 (USD MILLION)          151

TABLE 120         REST OF ASIA PACIFIC: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          151

TABLE 121         REST OF ASIA PACIFIC: INJECTION PEN MARKET FOR DIABETES THERAPY,

BY TYPE, 2022–2030 (USD MILLION)       152

TABLE 122        REST OF ASIA PACIFIC: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          152

TABLE 123         LATIN AMERICA: INJECTION PEN MARKET, BY COUNTRY,

2022–2030 (USD MILLION)          153

TABLE 124         LATIN AMERICA: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION) 153

TABLE 125         LATIN AMERICA: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          153

TABLE 126         LATIN AMERICA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2022–2030 (USD MILLION)  154

TABLE 127         LATIN AMERICA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          154

TABLE 128         BRAZIL: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          155

TABLE 129         BRAZIL: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 155

TABLE 130         BRAZIL: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          155

TABLE 131         BRAZIL: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 156

TABLE 132         MEXICO: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)          156

TABLE 133         MEXICO: INJECTION PEN MARKET, BY THERAPY, 2022–2030 (USD MILLION) 157

TABLE 134         MEXICO: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2022–2030 (USD MILLION)          157

TABLE 135         MEXICO: INJECTION PEN MARKET, BY END USER, 2022–2030 (USD MILLION) 157

TABLE 136         REST OF LATIN AMERICA: INJECTION PEN MARKET, BY TYPE,

2022–2030 (USD MILLION)          158

TABLE 137         REST OF LATIN AMERICA: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          158

TABLE 138         REST OF LATIN AMERICA: INJECTION PEN MARKET FOR DIABETES THERAPY,

BY TYPE, 2022–2030 (USD MILLION)       159

TABLE 139         REST OF LATIN AMERICA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          159

TABLE 140         MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY REGION,

2022–2030 (USD MILLION)          160

TABLE 141         MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY TYPE,

2022–2030 (USD MILLION)          160

TABLE 142         MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          161

TABLE 143         MIDDLE EAST & AFRICA: INJECTION PEN MARKET FOR DIABETES THERAPY,

BY TYPE, 2022–2030 (USD MILLION)       161

TABLE 144         MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          161

TABLE 145         GCC COUNTRIES: INJECTION PEN MARKET, BY TYPE, 2022–2030 (USD MILLION)     162

TABLE 146         GCC COUNTRIES: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          163

TABLE 147         GCC COUNTRIES: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2022–2030 (USD MILLION)  163

TABLE 148         GCC COUNTRIES: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          163

TABLE 149         REST OF MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY TYPE,

2022–2030 (USD MILLION)          164

TABLE 150         REST OF MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY THERAPY,

2022–2030 (USD MILLION)          164

TABLE 151         REST OF MIDDLE EAST & AFRICA: INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE, 2022–2030 (USD MILLION)  165

TABLE 152         REST OF MIDDLE EAST & AFRICA: INJECTION PEN MARKET, BY END USER,

2022–2030 (USD MILLION)          165

TABLE 153         INJECTION PEN MARKET: DEGREE OF COMPETITION  169

TABLE 154         INJECTION PEN MARKET: TYPE FOOTPRINT     174

TABLE 155         INJECTION PEN MARKET: THERAPY FOOTPRINT           175

TABLE 156         INJECTION PEN MARKET: REGION FOOTPRINT 176

TABLE 157         INJECTION PEN MARKET: LIST OF KEY STARTUPS/SMES              179

TABLE 158         INJECTION PEN MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES   179

TABLE 159         INJECTION PEN MARKET: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021–JULY 2024           182

TABLE 160         INJECTION PEN MARKET: DEALS, JANUARY 2021–JULY 2024              182

TABLE 161         INJECTION PEN MARKET: EXPANSIONS, JANUARY 2021–JULY 2024      183

TABLE 162         INJECTION PEN MARKET: OTHER DEVELOPMENTS, JANUARY 2021–JULY 2024 184

TABLE 163         NOVO NORDISK A/S: COMPANY OVERVIEW      185

TABLE 164         NOVO NORDISK A/S: PRODUCTS OFFERED       186

TABLE 165         NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021— JULY 2024         187

TABLE 166         NOVO NORDISK A/S: DEALS, JANUARY 2021— JULY 2024              187

TABLE 167         ELI LILLY AND COMPANY: COMPANY OVERVIEW          189

TABLE 168         ELI LILLY AND COMPANY: PRODUCTS OFFERED           190

TABLE 169         ELI LILLY AND COMPANY: DEALS, JANUARY 2021— JULY 2024              191

TABLE 170         ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2021— JULY 2024      191

TABLE 171         SANOFI: COMPANY OVERVIEW 193

TABLE 172         SANOFI: PRODUCTS OFFERED 194

TABLE 173         SANOFI: DEALS, JANUARY 2021— JULY 2024        195

TABLE 174         YPSOMED HOLDING AG: COMPANY OVERVIEW             196

TABLE 175         YPSOMED HOLDING AG: PRODUCTS OFFERED 197

TABLE 176         YPSOMED HOLDING AG: EXPANSIONS, JANUARY 2021— JULY 2024      198

TABLE 177         YPSOMED HOLDING AG: OTHER DEVELOPMENTS, JANUARY 2021— JULY 2024            198

TABLE 178         BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW              200

TABLE 179         BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED              201

TABLE 180         MERCK KGAA: COMPANY OVERVIEW    203

TABLE 181         MERCK KGAA: PRODUCTS OFFERED     204

TABLE 182         ASTRAZENECA: COMPANY OVERVIEW  205

TABLE 183         ASTRAZENECA: PRODUCTS OFFERED   206

TABLE 184         ASTRAZENECA: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2021— JULY 2024         207

TABLE 185         OWEN MUMFORD: COMPANY OVERVIEW          208

TABLE 186         OWEN MUMFORD: PRODUCTS OFFERED           208

TABLE 187         HASELMEIER: COMPANY OVERVIEW     209

TABLE 188         HASELMEIER: PRODUCTS OFFERED      209

TABLE 189         SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW        210

TABLE 190         SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED          211

TABLE 191         PFIZER INC.: COMPANY OVERVIEW       212

TABLE 192         PFIZER INC.: PRODUCTS OFFERED        213

TABLE 193         BIOCON: COMPANY OVERVIEW             214

TABLE 194         BIOCON: PRODUCTS OFFERED 215

TABLE 195         BIOCON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021— JULY 2024            216

TABLE 196         BIOCON: DEALS, JANUARY 2021— JULY 2024      216

TABLE 197         LUPIN: COMPANY OVERVIEW   217

TABLE 198         LUPIN: PRODUCTS OFFERED    218

TABLE 199         WOCKHARDT LTD.: COMPANY OVERVIEW        219

TABLE 200         WOCKHARDT LTD.: PRODUCTS OFFERED         220

TABLE 201         MEDTRONIC: COMPANY OVERVIEW     221

TABLE 202         MEDTRONIC: PRODUCTS OFFERED      222

TABLE 203         MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021— JULY 2024         223

TABLE 204         GERRESHEIMER AG: COMPANY OVERVIEW       224

TABLE 205         SHAILY ENGINEERING PLASTICS LTD.: COMPANY OVERVIEW              225

TABLE 206         SHL MEDICAL AG: COMPANY OVERVIEW           226

TABLE 207         EMPERRA GMBH E-HEALTH TECHNOLOGIES: COMPANY OVERVIEW        227

TABLE 208         NEMERA FRANCE SAS: COMPANY OVERVIEW    228

TABLE 209         JIANGSU DELFU MEDICAL DEVICE CO., LTD.: COMPANY OVERVIEW        229

TABLE 210         SOLTEAM MEDICAL: COMPANY OVERVIEW      230

TABLE 211         PHILIP-MEDISIZE- A MOLEX COMPANY: COMPANY OVERVIEW              231

TABLE 212         STEVANTO GROUP: COMPANY OVERVIEW        232

TABLE 213         WANHAI MEDICAL INSTRUMENTS CO., LTD.: COMPANY OVERVIEW        233

LIST OF FIGURES

FIGURE 1           INJECTION PEN MARKET SEGMENTATION        23

FIGURE 2           RESEARCH DESIGN       26

FIGURE 3           PRIMARY SOURCES       28

FIGURE 4           INJECTION PEN MARKET: BREAKDOWN OF PRIMARY INTERVIEWS

(BY COMPANY TYPE, DESIGNATION, AND REGION)      30

FIGURE 5           INJECTION PEN MARKET: BREAKDOWN OF PRIMARY INTERVIEWS:

SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS         30

FIGURE 6           MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS     31

FIGURE 7           MARKET SIZE ESTIMATION BASED ON REVENUE SHARE ANALYSIS          32

FIGURE 8           ILLUSTRATIVE EXAMPLE OF NOVO NORDISK A/S: REVENUE SHARE

ANALYSIS, 2023 32

FIGURE 9           MARKET SIZE ESTIMATION FOR INJECTION PEN DEVICES BASED

ON REVENUE SHARE ANALYSIS 34

FIGURE 10         ILLUSTRATIVE EXAMPLE OF YPSOMED AG: REVENUE SHARE ANALYSIS, 2023 35

FIGURE 11         INJECTION PEN MARKET: TOP-DOWN APPROACH        36

FIGURE 12         CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   37

FIGURE 13         DATA TRIANGULATION             38

FIGURE 14         INJECTION PEN MARKET, BY TYPE, 2024 VS. 2030 (USD MILLION)          41

FIGURE 15         INJECTION PEN MARKET, BY THERAPY, 2024 VS. 2030 (USD MILLION)          42

FIGURE 16         INJECTION PEN MARKET FOR DIABETES THERAPY, BY TYPE,

2024 VS. 2030(USD MILLION)     42

FIGURE 17         INJECTION PEN MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)          43

FIGURE 18         GEOGRAPHICAL SNAPSHOT OF INJECTION PEN MARKET, 2024–2029          44

FIGURE 19         GROWING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET            45

FIGURE 20         DIABETES SEGMENT AND JAPAN ACCOUNTED FOR LARGEST SHARES

IN ASIA PACIFIC INJECTION PEN MARKET IN 2023          46

FIGURE 21         CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD              47

FIGURE 22         DEVELOPING MARKETS TO ACCOUNT FOR HIGHER GROWTH

DURING FORECAST PERIOD     47

FIGURE 23         INJECTION PEN MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES        48

FIGURE 24         PATIENTS WITH CHRONIC DISEASES IN US, 1995–2030 (MILLION)        49

FIGURE 25         ESTIMATED DIABETIC POPULATION, BY REGION, 2029 VS. 2030 VS.

2040 (MILLION) 50

FIGURE 26         REVENUE SHIFT AND NEW REVENUE POCKETS FOR INJECTION PEN PROVIDERS      55

FIGURE 27         INJECTION PEN MARKET: SUPPLY CHAIN ANALYSIS      59

FIGURE 28         INJECTION PEN MARKET: PORTER’S FIVE FORCES ANALYSIS              62

FIGURE 29         INJECTION PEN MARKET: VALUE CHAIN ANALYSIS       64

FIGURE 30         CANADA: CLASS II MEDICAL DEVICE APPROVAL PROCESS              67

FIGURE 31         EUROPE: CE APPROVAL PROCESS FOR CLASS IIA MEDICAL DEVICES            68

FIGURE 32         PATENTS GRANTED WORLDWIDE, JANUARY 2014–JUNE 2024              74

FIGURE 33         PATENT ANALYSIS, JANUARY 2014–JUNE 2024    75

FIGURE 34         AVERAGE SELLING PRICE TREND OF INSULIN PENS, BY KEY PLAYER, 2023 (USD)      76

FIGURE 35         AVERAGE SELLING PRICE TREND OF GLP-1 PENS, BY KEY PLAYER, 2023 (USD)      77

FIGURE 36         INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY END USER    79

FIGURE 37         KEY BUYING CRITERIA, BY END USER    80

FIGURE 38         INJECTION PEN MARKET: ECOSYSTEM ANALYSIS          81

FIGURE 39         INVESTMENT AND FUNDING SCENARIO, 2018–2022       85

FIGURE 40         NORTH AMERICA: INJECTION PEN MARKET SNAPSHOT              119

FIGURE 41         ASIA PACIFIC: INJECTION PEN MARKET SNAPSHOT       139

FIGURE 42         REVENUE ANALYSIS OF KEY PLAYERS IN INJECTION PEN MARKET, 2021–2023       168

FIGURE 43         MARKET SHARE ANALYSIS OF KEY PLAYERS IN INJECTION PEN MARKET, 2023  169

FIGURE 44         INJECTION PEN MARKET: COMPANY EVALUATION MATRIX, 2023      172

FIGURE 45         INJECTION PEN MARKET: COMPANY FOOTPRINT         173

FIGURE 46         INJECTION PEN MARKET: COMPANY EVALUATION MATRIX

(STARTUPS/SMES), 2023             178

FIGURE 47         EV/EBITDA OF KEY VENDORS   180

FIGURE 48         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA OF KEY VENDORS             180

FIGURE 49         INJECTION PEN MARKET: BRAND/PRODUCT COMPARISON              181

FIGURE 50         NOVO NORDISK A/S: COMPANY SNAPSHOT (2023)        186

FIGURE 51         ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2023)              190

FIGURE 52         SANOFI: COMPANY SNAPSHOT (2023)   194

FIGURE 53         YPSOMED HOLDING AG: COMPANY SNAPSHOT (2023) 197

FIGURE 54         BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023)   201

FIGURE 55         MERCK KGAA: COMPANY SNAPSHOT (2023)      204

FIGURE 56         ASTRAZENECA: COMPANY SNAPSHOT (2023)    206

FIGURE 57         SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)          211

FIGURE 58         PFIZER INC.: COMPANY SNAPSHOT (2023)         213

FIGURE 59         BIOCON: COMPANY SNAPSHOT (2023) 215

FIGURE 60         LUPIN: COMPANY SNAPSHOT (2023)     218

FIGURE 61         WOCKHARDT LTD.: COMPANY SNAPSHOT (2023)          219

FIGURE 62         MEDTRONIC: COMPANY SNAPSHOT (2023)       222

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧